Halozyme Therapeutics Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Halozyme Therapeutics stock.
View analyst ratings for Halozyme Therapeutics or view top-rated stocks.

4 Wall Street research analysts have issued 1-year price targets for Halozyme Therapeutics' stock. Their HALO stock forecasts range from $42.00 to $60.00. On average, they anticipate Halozyme Therapeutics' stock price to reach $53.20 in the next year. This suggests a possible upside of 13.4% from the stock's current price.
View analysts' price targets for Halozyme Therapeutics or view top-rated stocks among Wall Street analysts.

Halozyme Therapeutics' stock was trading at $40.21 at the beginning of 2022. Since then, HALO stock has increased by 16.6% and is now trading at $46.90.
View the best growth stocks for 2022 here.

Halozyme Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Halozyme Therapeutics.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) released its quarterly earnings data on Tuesday, May, 10th. The biopharmaceutical company reported $0.43 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.45 by $0.02. The biopharmaceutical company had revenue of $117.30 million for the quarter, compared to analyst estimates of $128.25 million. Halozyme Therapeutics had a trailing twelve-month return on equity of 132.71% and a net margin of 92.23%. The company's quarterly revenue was up 31.8% compared to the same quarter last year. During the same period in the previous year, the business posted $0.34 EPS.
View Halozyme Therapeutics' earnings history.

Halozyme Therapeutics updated its FY 2022 earnings guidance on Tuesday, June, 7th. The company provided earnings per share guidance of $2.05-$2.20 for the period, compared to the consensus EPS estimate of $2.23. The company issued revenue guidance of $530.00 million-$560.00 million, compared to the consensus revenue estimate of $566.18 million.

12 employees have rated Halozyme Therapeutics CEO Helen Torley on Glassdoor.com. Helen Torley has an approval rating of 75% among Halozyme Therapeutics' employees.

Some companies that are related to Halozyme Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Seagen (SGEN), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Repligen (RGEN), Exact Sciences (EXAS), Exelixis (EXEL) and Ionis Pharmaceuticals (IONS).
View all of HALO's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Micron Technology (MU), Gilead Sciences (GILD), Athabasca Oil (ATH), NIC (EGOV), Allergan (AGN) and AbbVie (ABBV).

Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."

Halozyme Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.62%), William Blair Investment Management LLC (3.88%), Invesco Ltd. (3.86%), Snyder Capital Management L P (2.93%), Northern Trust Corp (1.63%) and Loomis Sayles & Co. L P (1.59%). Company insiders that own Halozyme Therapeutics stock include Connie Matsui, Dimitrios Chondros, Helen Torley, James M Daly, Jean-Pierre Bizzari, Jeffrey William Henderson, Kenneth J Kelley and Michael J Labarre.
View institutional ownership trends for Halozyme Therapeutics.

HALO stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Skandinaviska Enskilda Banken AB publ , Vanguard Group Inc., Invesco Ltd., Federated Hermes Inc., UBS Group AG, WINTON GROUP Ltd, and Eagle Asset Management Inc.. Company insiders that have sold Halozyme Therapeutics company stock in the last two years include Connie Matsui, Helen Torley, James M Daly, Jean-Pierre Bizzari, Jeffrey William Henderson, Kenneth J Kelley, and Michael J Labarre.
View insider buying and selling activity for Halozyme Therapeutics or view top insider-selling stocks.

HALO stock was acquired by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Loomis Sayles & Co. L P, Bernzott Capital Advisors, Sectoral Asset Management Inc., GW&K Investment Management LLC, Russell Investments Group Ltd., First Light Asset Management LLC, and Renaissance Technologies LLC.
View insider buying and selling activity for Halozyme Therapeutics or or view top insider-buying stocks.

Shares of HALO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HALO stock can currently be purchased for approximately $46.90.

Halozyme Therapeutics (NASDAQ:HALO) has a market capitalization of $6.47 billion and generates $443.31 million in revenue each year. The biopharmaceutical company earns $402.71 million in net income (profit) each year or $2.989990 on an earnings per share basis.

Halozyme Therapeutics employs 145 workers across the globe.

Halozyme Therapeutics was founded in 1998.

Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121-1345. The official website for Halozyme Therapeutics is www.halozyme.com. The biopharmaceutical company can be reached via phone at 858-794-8889, via email at [email protected], or via fax at 858-704-8311.